Applicant: Michael Anthony Cawl

Serial No.: 09/423,684

Filed

: November 10, 1999

Page

ney's Docket No.: 00537-161002 / BPC051/US/PCT/US

## REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert sequence identifiers in the specification that correspond with the sequence disclosures in the Sequence Listing filed on October 30, 2000. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 5 September 2001

Reg. No. 40,024

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804 Telephone: (617) 542-5070

Facsimile: (617) 542-8906

20297191.doc

Applicant: Michael Anthony Cawtone et al.

Serial No.: 09/423,684

Filed: November 10, 1999

Page : 11

ney's Docket No.: 00537-161002 / BPC051/US/PCT/US

## "Version With Markings to Show Changes Made"

## In the specification:

Paragraph beginning at page 10, line 27, has been amended as follows:

Examples of somatostatin agonists include, but are not limited to, the following somatostatin analogs which are disclosed in the above-cited references:

```
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub> (BIM-23014);
       H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;
       H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;
       H-D-β-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;
       H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH<sub>2</sub>;
       H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH<sub>2</sub>;
       H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH;
       H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
       H-Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH;
       H-Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH;
       H-Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
       H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol (Octreotide);
       H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;
       H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;
       H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;
       H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;
       H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH<sub>2</sub>;
       H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;
       Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp-Thr-NH<sub>2</sub> (an amide bridge formed between
Lys* and Asp);
       Ac-hArg (Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;
```

Ac-D-hArg (Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg (Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Applicant: Michael Anthony Cawing he et al.

Serial No.: 09/423,684

Filed: November 10, 1999

Page : 12

ney's Docket No.: 00537-161002 / BPC051/US/PCT/US

Ac-D-hArg (Et)<sub>2</sub>-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

 $Ac\text{-}L\text{-}hArg\ (Et)_2\text{-}Cys\text{-}Phe\text{-}D\text{-}Trp\text{-}Lys\text{-}Thr\text{-}Cys\text{-}Thr\text{-}NH_2;$ 

 $Ac\text{-}D\text{-}hArg\ (CH_2CF_3)_2\text{-}Cys\text{-}Phe\text{-}D\text{-}Trp\text{-}Lys\text{-}Thr\text{-}Cys\text{-}Thr\text{-}NH_2;$ 

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH<sub>2</sub>;

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;

 $Ac\text{-}L\text{-}hArg\ (CH_2CF_3)_2\text{-}Gly\text{-}Cys\text{-}Phe\text{-}D\text{-}Trp\text{-}Lys\text{-}Thr\text{-}Cys\text{-}Thr\text{-}NH_2;$ 

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys (Me)-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg (CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys (Me)-Thr-Cys-Thr-NHEt;

Ac-hArg (CH<sub>3</sub>, hexyl)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

H-hArg (hexyl<sub>2</sub>)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg (Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;

 $Ac\text{-}D\text{-}hArg\ (Et)_2\text{-}Gly\text{-}Cys\text{-}Phe\text{-}D\text{-}Trp\text{-}Lys\text{-}Thr\text{-}Cys\text{-}Phe\text{-}NH_2;$ 

 $Propionyl-D-hArg\ (Et)_2-Gly-Cys-Phe-D-Trp-Lys\ (iPr)-Thr-Cys-Thr-NH_2;$ 

Ac-D-β-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg (Et)-NH<sub>2</sub>;

Ac-D-Lys (iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-D- hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

 $Ac-D-hArg\ (CH_2CF_3)_2-D-\ hArg\ (CH_2CF_3)_2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH_2;$ 

Ac-D-hArg (Et)<sub>2</sub>-D-hArg (Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

 $Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH_2;\\$ 

 $H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH_2;\\$ 

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH<sub>2</sub>;

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH<sub>2</sub>;

 $H\text{-}Bmp\text{-}Tyr\text{-}D\text{-}Trp\text{-}Lys\text{-}Val\text{-}Cys\text{-}\beta\text{-}Nal\text{-}NH_2;}$ 

H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;

 $H\text{-}D\text{-}Phe\text{-}Cys\text{-}Tyr\text{-}D\text{-}Trp\text{-}Lys\text{-}Abu\text{-}Cys\text{-}Thr\text{-}NH_2;$ 

 $H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-\beta-Nal-NH_2;\\$ 

 $H-pentafluoro-D-Phe-Cys-Tyr-D-Trp-Lys-Lys-Val-Cys-Thr-NH_2;\\$ 

 $Ac-D-\beta-Nal-Cys-pentafluoro-Phe-D-Trp-Lys-Val-Cys-Thr-NH_2;\\$ 

 $H-D-\beta-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-\beta-Nal-NH_2$ ;

Applicant: Michael Anthony Cawtone et al.

Serial No.: 09/423,684

Filed: November 10, 1999

Page : 13

ney's Docket No.: 00537-161002 / BPC051/US/PCT/US

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>; H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>; H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>; Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>; H-D-Phe-Cys-β-Nal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>; H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH<sub>2</sub>; cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe); cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe); cyclo(Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe); cvclo(N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe); cyclo(Pro-Tyr-D-Trp-Lys-Thr-Phe); cyclo(Pro-Phe-D-Trp-Lys-Thr-Phe); cyclo(Pro-Phe-L-Trp-Lys-Thr-Phe) (SEQ ID NO:1); cyclo(Pro-Phe-D-Trp(F)-Lys-Thr-Phe); cyclo(Pro-Phe-Trp(F)-Lys-Thr-Phe) (SEQ ID NO:2); cyclo(Pro-Phe-D-Trp-Lys-Ser-Phe); cyclo(Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe); cyclo(D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe); cyclo(D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe); cyclo(D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe); cyclo(D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr); cyclo(Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe); cyclo(Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe); cyclo(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe); cyclo(N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe); cyclo(Pro-Tyr-D-Trp-4-Amphe-Thr-Phe); cyclo(Pro-Phe-D-Trp-4-Amphe-Thr-Phe); cyclo(N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe); cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba); cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba);

Applicant: Michael Anthony Cawt

Serial No.: 09/423,684

: November 10, 1999 Filed

Page

ney's Docket No.: 00537-161002 / BPC051/US/PCT/US

```
cyclo(Asn-Phe-D-Trp-Lys-Thr-Phe);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH<sub>2</sub>)<sub>4</sub>CO);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-β-Ala);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH;
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe);
cvclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gly);
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly);
cyclo(Asn-Phe-Phe-D-Trp(F)-Lys-Thr-Phe-Gaba);
cvclo(Asn-Phe-Phe-D-Trp(NO<sub>2</sub>)-Lys-Thr-Phe-Gaba);
cyclo(Asn-Phe-Phe-Trp(Br)-Lys-Thr-Phe-Gaba) (SEQ ID NO:3);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I)-Gaba);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But)-Gaba);
cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH;
cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH;
cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys)-OH;
cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys)-OH;\\
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba);
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba);
cyclo(Phe-Phe-D-Trp(5F)-Lys-Thr-Phe-Phe-Gaba);
cyclo(Asn-Phe-Phe-D-Trp-Lys(Ac)-Thr-Phe-NH-(CH<sub>2</sub>)<sub>3</sub>-CO);
cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
cyclo(Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> (BIM-23268);
H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH<sub>2</sub> (BIM-23284);
H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH2 (BIM-23295); and
H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> (BIM-23313).
```

Applicant: Michael Anthony Cawt

Serial No.: 09/423,684

Filed

: November 10, 1999

Page

ney's Docket No.: 00537-161002 / BPC051/US/PCT/US

## In the claims:

Claim 23 has been amended as follows:

(Amended) A method according to claim 1 wherein the somatostatin agonist is 23.

H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>,

H-D-β-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH,

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH,

H-Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH,

H-Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH,

H-Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH,

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol,

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,

H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,

Ac-D-Phe-Lys\*-Tyr-D-Trp-Lys-Val-Asp-Thr-NH<sub>2</sub> (an amide bridge formed between Lys\* and Asp),

Ac-hArg (Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-D-hArg (Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-D-hArg (Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-D-hArg (Et)<sub>2</sub>-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-L-hArg (Et)<sub>2</sub>-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Applicant: Michael Anthony Cawtone et al.

Serial No.: 09/423,684

Filed: November 10, 1999

Page : 16

161002 / BPC051/US/PCT/US

ney's Docket No.: 00537-

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH<sub>2</sub>,

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt,

Ac-L-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys (Me)-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys (Me)-Thr-Cys-Thr-NHEt,

Ac-hArg (CH<sub>3</sub>, hexyl)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

H-hArg (hexyl<sub>2</sub>)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-D-hArg (Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt,

Ac-D-hArg (Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH<sub>2</sub>,

Propionyl-D-hArg (Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys (iPr)-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-D-β-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg (Et)-NH<sub>2</sub>,

Ac-D-Lys (iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-D- hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-D-hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-D- hArg (CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH<sub>2</sub>,

Ac-D-hArg (Et)<sub>2</sub>-D-hArg (Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>,

Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH<sub>2</sub>,

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH<sub>2</sub>,

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH<sub>2</sub>,

H-Bmp-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>,

H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>,

H-pentafluoro-D-Phe-Cys-Tyr-D-Trp-Lys-Lys-Val-Cys-Thr-NH<sub>2</sub>,

Ac-D-β-Nal-Cys-pentafluoro-Phe-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>,

H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>,

H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>,

Applicant: Michael Anthony Cawl

Serial No.: 09/423,684

Filed

: November 10, 1999

Page

: 17

ney's Docket No.: 00537-161002 / BPC051/US/PCT/US

H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>, Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>, H-D-Phe-Cys-β-Nal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>, H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH<sub>2</sub>, cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe), cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe), cyclo(Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe), cyclo(N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe), cyclo(Pro-Tyr-D-Trp-Lys-Thr-Phe), cyclo(Pro-Phe-D-Trp-Lys-Thr-Phe), cyclo(Pro-Phe-L-Trp-Lys-Thr-Phe) (SEQ ID NO:1), cyclo(Pro-Phe-D-Trp(F)-Lys-Thr-Phe), cyclo(Pro-Phe-Trp(F)-Lys-Thr-Phe) (SEQ ID NO:2), cyclo(Pro-Phe-D-Trp-Lys-Ser-Phe), cyclo(Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe), cyclo(D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe), cyclo(D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe), cyclo(D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe), cyclo(D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr), cyclo(Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe), cyclo(Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe), cyclo(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe), cyclo(N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe), cyclo(Pro-Tyr-D-Trp-4-Amphe-Thr-Phe), cyclo(Pro-Phe-D-Trp-4-Amphe-Thr-Phe), cyclo(N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe), cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba), cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba), cyclo(Asn-Phe-D-Trp-Lys-Thr-Phe),

cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH<sub>2</sub>)<sub>4</sub>CO),

Applicant: Michael Anthony Cawth et al

Serial No.: 09/423,684

Filed: November 10, 1999

Page : 18

A ney's Docket No.: 00537-161002 / BPC051/US/PCT/US

cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-β-Ala), cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH, cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe), cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gly), cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba), cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly), cyclo(Asn-Phe-Phe-D-Trp(F)-Lys-Thr-Phe-Gaba), cyclo(Asn-Phe-Phe-D-Trp(NO<sub>2</sub>)-Lys-Thr-Phe-Gaba), cyclo(Asn-Phe-Phe-Trp(Br)-Lys-Thr-Phe-Gaba) (SEQ ID NO:3), cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I)-Gaba), cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But)-Gaba), cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH, cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH, cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys)-OH, cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys)-OH, cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba), cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba), cyclo(Phe-Phe-D-Trp(5F)-Lys-Thr-Phe-Phe-Gaba), cyclo(Asn-Phe-Phe-D-Trp-Lys(Ac)-Thr-Phe-NH-(CH<sub>2</sub>)<sub>2</sub>-CO), cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba), cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba), cyclo(Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba), H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>, H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH<sub>2</sub>, H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>, or

H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>.